Boris Cherny was asked at Brainstorm Tech if he was concerned about the rapid progress of AI: "Yes." ...
Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...
Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Six Proto6 flaws in protobuf.js enable RCE and DoS attacks; patched in versions 7.5.6 and 8.0.2 to protect Node.js services.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
States across the country are moving ahead with artificial intelligence regulations despite President Donald Trump's efforts ...
Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results